Boston Scientific (NYSE:BSX) added another product to its recent string of regulatory approvals, announcing European CE Mark approval and immediate commercial launch for the company’s Agent paclitaxel-coated balloon catheter.
The device, which is essentially a drug-laced version of the company’s Emerge balloon platform, was approved in treatment of both in-stent restenosis and de novo small vessel coronary disease, Boston Scientific announced today.
The Massachusetts medical device maker has been on a roll, announcing one regulatory win after another this month. Earlier this week the company announced FDA approval for its Rebel bare-metal stent and earlier this month Boston Scientific landed CE Mark approval for a new mid-size version of its Lotus aortic valve. Just before that the company touted CE Mark for its Ranger drug-eluting balloon.
BSX shares were up 1.5% today, trading at $13.21 as of about 3:25 p.m. EST after the company saw positive momentum from a Wall Street-beating 2nd-quarter financial report and a heightened outlook for the year.